- 1 Analysis of SARS-CoV-2 mutations associated with resistance to therapeutic monoclonal antibodies that
- 2 emerge after treatment.
- 3
- 4 Daniele Focosi^{1,#}
- 5 Scott McConnell²
- 6 David J. Sullivan²
- 7 Arturo Casadevall²
- 8
- ⁹ ¹North-Western Tuscany Blood Bank, Pisa University Hospital, Italy.
- ²Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public
- 11 Health, Baltimore, MD 21205, USA.
- 12
- 13 [#]corresponding author: <u>daniele.focosi@gmail.com.</u>
- 14
- 15 **Word counts**: abstract: 235; body 1941.

Keywords: COVID-19; SARS-CoV-2; monoclonal antibodies; sotrovimab; casirivimab; imdevimab;
 tixagevimab; cilgavimab.

- **Author contributions**: D.F. performed literature search and wrote the first draft. A.C. revised the manuscript. D.J.S. revised the manuscript and curated Table 3. S.M. designed Figure 2.
- 20 **Conflict of interest statement**: We declare we have no COI related to this manuscript.
- 21 Funding: none.
- 22

23 Abstract

24 The mutation rate of the Omicron sublineage has led to baseline resistance against all previously 25 authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more antiviral mAbs will be 26 authorized in the future, it is relevant to understand how frequently treatment-emergent resistance has 27 emerged so far, under different combinations and in different patient subgroups. We report the results 28 of a systematic review of the medical literature for case reports and case series for treatment-emergent 29 immune escape, which is defined as emergence of a resistance-driving mutation in at least 20% of 30 sequences in a given host at a given timepoint. We identified 31 publications detailing 201 cases that 31 included different variants of concern (VOC) and found that the incidence of treatment emergent-32 resistance ranged from 10% to 50%. Most of the treatment-emergent resistance events occurred in 33 immunocompromised patients. Interestingly, resistance also emerged against cocktails of two mAbs, 34 albeit at lower frequencies. The heterogenous therapeutic management of those cases doesn't allow

- 35 inferences about the clinical outcome in patients with treatment-emergent resistance. Furthermore, we
- 36 noted a temporal correlation between the introduction of mAb therapies and a subsequent increase in
- 37 SARS-CoV-2 sequences across the globe carrying mutations conferring resistance to that mAb, raising
- 38 concern as to whether these had originated in mAb-treated individuals. Our findings confirm that
- 39 treatment-emergent immune escape to anti-Spike mAbs represents a frequent and concerning
- 40 phenomenon and suggests that these are associated with mAb use in immunosuppressed hosts.

41 Introduction

42 Passive antibody pre-exposure and post-exposure prophylaxis and treatments are much needed for 43 immunocompromised patients at risk of COVID-19 progression. For them, anti-Spike monoclonal 44 antibodies (mAb) have been the treatment of choice since early 2021. The biologicals were safe, well 45 tolerated and efficient at preventing disease and reducing the likelihood of progression to severe 46 disease. Unfortunately, the advent of the Omicron VOC progressively defeated the emergency use 47 authorized mAbs, leaving all revoked by the US Food and Drug Administration at the time of writing. The 48 COVID-19 pandemic has represented the first instance of large-scale deployments of passive 49 immunotherapies against an infectious agent, and with persistence at epidemic levels and fluctuations 50 in the dominant variants, it is possible that this scenario will persist for more years. This in turn provides 51 a unique opportunity to study the phenomenon of emerging resistance to antibody-based therapeutics. 52 The emergence of mAb-resistant variants after individualized therapy has potential public health 53 implications if these viruses re-enter the general population and are able to evade vaccine or prior 54 infection immunity by virtue of their mutations (Casadevall and Focosi, 2023)Here we analyzed mAbs 55 resistance patterns following therapy principally in immunosuppressed but sometimes in 56 immunocompetent COVID-19 patients.

57 Materials and methods

58 Inferring baseline resistance to anti-Spike monoclonal antibodies.

59 The Stanford University Coronavirus Antiviral & Resistance Database is a comprehensively curated 60 collection of published data on the susceptibility of SARS-CoV-2 variants to anti-Spike mAbs and the 61 plasma from previously infected and/or vaccinated persons. It also records the Spike protein mutations that are selected by mAbs and that emerge in persons experiencing prolonged infection (Tzou et al., 62 63 2020). It is publicly accessible at https://covdb.stanford.edu/. For each authorized anti-Spike mAb, we 64 manually scanned mutations associated with >5-fold median reduction in neutralizing antibody (nAb) 65 titers from primary research listed in search results provided at https://covdb.stanford.edu/searchdrdb/?form only. The cutoff was arbitrarily chosen by the authors based on former literature suggesting 66 loss of therapeutic efficacy. 67

68 Literature search

69 On February 1 2023, we searched PubMed, bioRxiv and medRxiv repositories for literature published 70 since January 1 2020 to February 1 2023 using English language as a restriction. We used the query 71 "("sotrovimab" OR "tixagevimab" OR "cilgavimab" OR "bamlanivimab" OR "etesevimab" OR "casirivimab" 72 OR "imdevimab" OR "bebtelovimab" OR "regdanvimab") AND ("resistance" OR "escape" OR "evasion" 73 OR "evolution")". The PRISMA flowchart is reported in Figure 1. We excluded all primary research on 74 baseline (as opposed to treatment-emergent) resistance and all secondary research. We collected data 75 about sample size, underlying immunosuppression and incidence of *de novo* mutations at Spike residues 76 associated with mAb escape.

77

78 Determining the temporal relationship between mAb authorization and global prevalence

79 On February 1 2023 we searched CoV-Spectrum.org (Chen et al., 2021a) for worldwide prevalence of

80 SARS-CoV-2 sublineages carrying either at least one mutation conferring resistance to a given mAb or

just the major resistance associated mutations (i.e., Q493X for bamlanivimab and etesevimab, R346X for

- 82 cilgavimab, K444X for bebtelovimab).
- 83

84 Mapping treatment emergent mutations to the structures of Spike:mAb complexes

All three-dimensional molecular representations were generated with PyMOL 2.5.2 (Schrodinger). Deposited structures of therapeutic mAbs in complex with the Spike protein were obtained from the Protein Database (PDB) under the accession numbers 7KMG (bamlanivimab), 7C01 (etesevimab), 6XDG

88 (casirivimab/imdevimab), 7L7E (cilgavimab), 7L7D (tixagevimab) and 6WPS (sotrovimab).

89

90 Results

91 The individual Spike amino acid mutations conferring resistance to each mAb are summarized in Table 1.

92 A review of 31 publications reporting mAb resistance yielded a list of Spike protein mutations associated

with mAb resistance (Table 2). From these publications we identified 201 out of 1060 patients who

94 experienced emergence of resistant SARS-CoV-2 after treatment with one of the anti-Spike mAb. As

- 95 expected from real-world indications and usage, the majority of these patients were
- 96 immunocompromised, but immunocompetent patients were also noted (Sabin et al., 2022).
- 97 26 publications reported incidence rates while investigating a cohort: among them the incidences varied
- 98 between 0% to 100% with overall 195/1079 or 18.1%. In particular bamlanivimab (n=5) ranged from 11
- to 83%, sotrovimab (n=10) from 16 to 100%, while dual mAbs (n=10) ranged from 0% to 50%.

100 The majority of resistant cases from cohorts were reported after mAb monotherapies bamlanivimab

101 (23/160-14%) or sotrovimab (131/427-31%) as opposed to mAb cocktails bamlanivimab+ etesevimab

102 (15/270-6%) or casirivimab+ imdevimab (16/185-9%) (Table 3). The cilgavimab+ tixagevimab essentially

103 had a single active mAb during most of its deployment and the rate in the series cohorts was similar to

- 104 single monoclonals (10/37-27%).
- 105 Studies with a specific mAb or mAb cocktail largely reported the same set of emerging Spike mutations 106 (e.g., Q493X and E484X for bamlanivimab, P337X and E340X for sotrovimab).

107 By guerying the Spike protein sequence database for the major mutations associated with mAb-108 resistance we noted that these mutations emerged in the general population across the globe shortly 109 after marketing authorization of the mAbs to whom they confer resistance (Figure 3). The most striking 110 examples are the emergence of S:Q493R (the single mutation conferring resistance to both 111 bamlanivimab and etesevimab, in addition to casirivimab and regdanvimab) in Omicron BA.1 shortly 112 after the massive deployment of bamlanivimab/etesevimab cocktail, and the emergence of S:R346X in 113 many converging Omicron sublineages shortly after the massive deployment of cilgavimab for post-114 exposure prophylaxis in immunosuppressed patients. There was a single case report of bebtelovimab 115 resistance (S:V445A post treatment in an immunocompromised patient with the B.1.23 lineage.

116

117 Discussion

118 The emergence of mAb treatment resistance during therapy is a common and consistent phenomenon. 119 The discrepancy between the diversity of mutations reported in vitro (Table 1) and the few ones 120 detected in vivo (Table 2) can be explained by various factors. First, not all mutants selected in vitro are 121 fit enough to compete within the intrahost guasispecies swarm. Fitness would include the ability to bind 122 to its cellular receptor as well capacity for virion stability and assembly. The large number of mutations 123 shown to confer resistance in vitro that are not reflected in the clinical data could be rationalized by the 124 fact that a reduction in nAb titers measured in vitro reflects a defect in antibody binding to Spike 125 variants but does not report on the relative efficacy of ACE2 binding compared to the ancestral Spike. 126 Second, in many cases some mutations were already occurring at baseline (e.g., F486X in patients 127 treated with tixagevimab). Third, among the residues wild-type at baseline, the mutations associated 128 with the highest fold-reduction in neutralization have been more commonly reported: while this could 129 be a notoriety bias by the investigators (placing more attention to the mutations which have been 130 previously reported), it is likely that as soon as one of the highly resistant mutations emerges, 131 emergence of additional mutations do not provide any further fitness advantage.

No cases of treatment-emergent resistance have been reported in the medical literature after
regdanvimab: this is likely due to usage much limited in time and locations across the globe.
Regdanvimab is not effective against Omicron lineages, limiting its use toa few weeks in the end 2021.

135 Most anti-Spike mAbs authorized thus far were not formally investigated in randomized controlled 136 trials (RCT) involving immunocompromised patients prior to deployment (Focosi et al., 2022a). 137 Immunocompromised patients are at increased risk for anti-Spike mAb treatment-emergent resistance 138 for multiple risk factors: higher basal viral load, higher likelihood of viral persistence because of inadequate immune response, and contraindications to other directly-acting antivirals (Casadevall and 139 140 Focosi, 2023). Resistance monitoring is not routinely performed after outpatient mAb treatment, and 141 viral sequencing interpretation requires paying attention to minoritarian sequences within the quasi-142 species swarm (Vellas et al., 2022a).

143 Despite FDA deauthorization, many US physicians continued prescription of deauthorized anti-Spike 144 mAbs(Anderson et al., 2022), mostly based on personal beliefs in discrepancies between in vitro and in vivo activities. The latter phenomenon has been much amplified across Europe (Focosi and Tuccori, 145 146 2022), where EMA has never withdrew a single authorized mAb to date, and only sporadically issued 147 alerts about possible basal resistance. In addition, a plethora of uncontrolled or poorly controlled 148 literature is advocating continued efficacy of anti-Spike mAbs based on marginal gains in surrogate 149 endpoints in non-RCTs (Harman et al., 2022) or no change in hospitalization rates of outpatients (Patel 150 et al., 2023). While binding affinity seems a robust surrogate endpoint, advocates of residual in vivo 151 activity argue that the concentrations achieved by mAbs in vivo can overcome several degrees of 152 baseline resistance to neutralization or that alternative effector function still persists(Stadler et al., 2022a; Stadler et al., 2022b; Wu et al., 2022). Both arguments do not seem robust: with IC₅₀ above 1,000 153 154 (Cao et al., 2022) antigen binding by the mAb is compromised, and effector functions other than 155 neutralization invariably require binding to the virus to activate Fc-receptors. Under the current variant 156 soup (Focosi et al., 2023), the incompatible turnaround time of viral sequencing and therapeutics 157 delivery, tools to predict basal efficacy of anti-Spike mAbs based on regional genomic surveillance have 158 been developed (Focosi, 2023).

Of interest, several cases of mAb-treatment-emergent immune escape were rescued with COVID-19 convalescent plasma (Halfmann et al., 2022; Pommeret et al., 2021), which, in contrast to mAbs, is polyclonal and thus more difficult to defeat by viral evolution.

162 We note that in many patients the emergence of mAb resistance was associated with only one amino 163 acid substitution in the epitope, establishing the high vulnerability of monotherapy for selecting 164 resistant variants. Emergence of resistance requires selection of mutant viruses that are fit for 165 replication and that could explain the repeated independent isolations of variants with mutations at 166 specific residues, such as in position 484 with bamlanivimab monotherapy. For some mAbs, the 167 generated footprint is so unique (e.g. S:340X after sotrovimab) that baseline sequencing is not needed 168 to confirm treatment emergence (S:340X being exceedingly rare in GISAID). The transmissibility of such mAb treatment-generated lineages remains a major concern, and it has been formally demonstrated in 169 170 at least one study (Sabin et al., 2022). Clinical reports of treatment-emergent resistance in response to 171 therapeutic mAbs reviewed here encompass nearly every epitope of the receptor binding domain (RBD). 172 including all 3 receptor binding motif epitopes and the cross reactive S309 site (Figure 2F). Despite 173 partial or complete overlap of antibody epitope on RBD with the ACE2 interface, these positions 174 demonstrate remarkable mutability while maintaining receptor affinity.

175 Since therapeutic mAbs ultimately trace their ancestry to immune B cells in humans, the emergence of 176 mAb resistance mutations poses the theoretical concern that once these occur in immunosuppressed 177 individuals the mAb-resistant variants can spread to immunocompetent populations, bypass existing 178 immunity, and create new waves of infection (Casadevall and Focosi, 2023). Consistent with this concern 179 we found a temporal association between the introduction of the mAb and an increase in frequency in 180 the SARS-CoV-2 Spike protein sequence database. Such temporal association could be explained by a scenario whereby the emergence of these variants in immunosuppressed hosts was followed by their 181 182 spread among the general population. Such mutations would have created antigenically distinct viruses 183 that could have an advantage in bypassing established immunity in the general population from 184 vaccination and prior infection as these occur in a critical neutralizing epitope. We caution that 185 association does not imply causation and that other interpretations are possible. For example, immunity 186 to previous infection waves could be another possible driver for selection of novel Spike variants, and 187 the possibility of viral transitioning through animal reservoirs remains as possibility since Q493R is a 188 mouse-adapting mutation, which in turn suggests the possibility of reverse zoonosis. Nevertheless, the 189 temporal association between mAb introduction in clinical practice and increased frequency of 190 mutations conferring resistance to that mAb is concerning and suggest that future use of mAb therapies 191 in immunocompromised populations should consider the use of cocktails and/or combination therapy 192 with small molecule antivirals. Cocktails-of-three or more anti-Spike mAbs with non-overlapping 193 epitopes could minimize the chances for immune escape.

- 194
- 195

Figure 1. PRISMA flowchart for study selection.

197

198 Figure 2. Resistance mutations on the Spike receptor binding domain (RBD) reported after treatment 199 with authorized anti-Spike mAbs. A-D) The complex structures of RBD and corresponding therapeutic 200 mAbs are represented as space-filling surfaces, where the RBD is colored black, the receptor binding 201 motif (residues 438-507) is colored dark gray, and corresponding escape mutations are highlighted in 202 yellow. In the middle panel, the entire RBD-mAb complex is depicted, and expanded and rotated views 203 of each interface are presented in boxes on each side of the main complex. The interacting mAb is 204 partially transparent to enable visualization of the full RBD paratope and reported resistance mutations 205 are labeled. A) The structural complex of the bamlanivimab/etesevimab mAb cocktail with RBD is 206 depicted. Bamlanivimab and etesevimab (PDBID 7KMG, 7C01) are colored blue and red, respectively. B) 207 The structural complex of the casirivimab/imdevimab mAb cocktail (REGN-CoV) with RBD is depicted. 208 Casirivimab and imdevimab (PDBID 6XDG) are colored salmon and dark green, respectively. C) The 209 structural complex of the cilgavimab/tixagevimab mAb cocktail with RBD is depicted. Cilgavimab and 210 tixagevimab (PDBID 7L7E, 7L7D) are colored purple and cyan, respectively. D) The structural complex of 211 the sotrovimab mAb monotherapy with RBD is depicted. Sotrovimab (PDBID 6WPS) is colored light 212 green. E) A summary of the reported treatment-emergent resistance mutations on RBD across all 213 approved anti-Spike therapeutic mAbs are highlighted on the structure of RBD, shown with the front 214 face, back face and top RBM view. Escape mutations in the RBM are highlighted in blue, non-RBM 215 mutations are colored red. F) The complexes of the each of the mAbs in complex with RBD are depicted, 216 colored as in panels A-D, to illustrate the relative binding angles and epitopes of each mAb.

217

Figure 3. Timeline of anti-Spike mAb authorizations and emergence of key Spike mutations associated with mAb resistance. Figure generated using Cov-Spectrum.org (Chen et al., 2021a)

Table 1. Spike mutations associated with mAb resistance in *in vitro* studies. Bold characters show the ones that have been detected as emerged *in vivo* after treatment with the specific mAb. In cases where the exact amino acid change has not been studied *in vitro*, only the residue is highlighted. Number within parentheses represent the median fold-reduction in neutralizing antibody titers.

mAb Spike mutation	
cilgavimab S: 346 I (> 200 (FDA, 2021)), S:444E (>200 (FDA, 2021; House et al.,	2022)), S:444Q
(>200 (FDA, 2021; House et al., 2022)), S: 444R (>200 (FDA, 202	1)), S:445A (36
(FDA, 2021)) , S:446S (3.7 (Ai et al., 2022; Liu et al., 2021; Tada	a et al., 2022a;
Wang et al., 2022b; Zhou et al., 2021)), S:447R (472 (House et al.,	2022)), S:450D
(382 (House et al., 2022), S:450K (9 (FDA, 2021)), S: 452 R (5 (FDA,	2021; House et
al., 2022; Wang et al., 2022a))	
tixagevimab S:371F (26 (Ai et al., 2022; Iketani et al., 2022; Zhou et al., 2022),	S:484A (4.9 (Ai
et al., 2022; Liu et al., 2021; Tada et al., 2022a)), S:484D (7 (FDA,	2021)), S:484K
(8.1 ((Annavajhala et al., 2021; Chen et al., 2021b; FDA, 2021	1; Wang et al.,
2021b; Wang et al., 2021d), S:486S (>600 (FDA, 2021)), S:486V (1	135 (FDA, 2021;
Wang et al., 2022a)), S:493R (6.5 (Ai et al., 2022; FDA, 2021; Li	u et al., 2021)),
S:990A (6.1 (FDA, 2021)), S:1009I (8.2 (FDA, 2021))	
bebtelovimab S:444N (> 1000), S:444Q (>140 (Westendorf et al., 2022)), S:	444T (>1000),
S:445A (>90 (Westendorf et al., 2022)), S:445F (369), S:445G (,>730), S:446D
(69), S:446R (7), S:446V (5.5 (Westendorf et al., 2022)),	S:499H (>1000
(Westendorf et al., 2022)), S:499R (>1000 (Westendorf et al., 202	22)), S:449S (45
(Westendorf et al., 2022))	
sotrovimab S: 337 H (6 (Cathcart et al., 2021)), S: 337L (180 (Cathcart et al.,	2021)), S: 337R
(>192 (Cathcart et al., 2021)), S: 337 1 (7 (Cathcart et al., 2021))	, S: 340A (>100
(Cathcart et al., 2021)), S: 340D (12 (Cathcart et al., 2021; Gliga	i et al., 2022)),
S:340G(22) (Cathcart et al., 2021)), $S:340K(>297)$ (Cathcart et al.	, 2021; Gliga et
al., 2022; Yi et al., 2021)), S: 340Q (>50 (Cathcart et al., 2021))), S:340V (>200
(Cathcart et al., 2021)), $5:3561$ (5.9 (Cathcart et al., 2021)), $5:371$.	F (13 (A1 et al.,
2022; Iketani et al., 2022; Zhou et al., 2022)), $S:37$ IL (I2 (Ai et al., 2021)), $S:37$ IL (I2 (Ai et al.	2022; Liu et al.,
2021; 1 ada et al., 2022a; Zhou et al., 2021)), 5:57/K (>704 (Cathcart	et al., 2021))
$\begin{array}{c} \text{casirivimab} \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Zhou et al., } 2022)), \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022), \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022), \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022), \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022), \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022), \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \text{ Iketani et al., } 2022; \\ \text{S:3/1F} (14 (A1 \text{ et al., } 2022; \text{ Iketani et al., } 2022; I$:405N (11 (A1 et
al., 2022; Iketani et al., 2022; Zhou et al., 2022)), 5:406D (51), 5:406 al. 2021)), $c.417E$ (165 (Beauxiet al., 2020)), $c.417E$ (61 (Beauxiet al., 2020))	$\frac{500}{2020}$ $\frac{64}{51arr}$ $\frac{51arr}{2020}$
al., 2021)), 5:417 E (105 (Baum et al., 2020)), 5:417 K (61 (Baum et al.) (40 (Du et al., 2022), EDA, 2022 , Liu et al., 2021 , Tada et al., 202	(, 2020)), 5:417N
(40) (Du et al., 2022; FDA, 2022; Liu et al., 2021; Tada et al., 202 2022a: Tada et al., 2022b: Warrs at al., 2021b: Warrs at al., 2021	na; nada et al.,
2022a; Tada et al., $2022b$; Wang et al., $2021b$; Wang et al., 2021	C; wang et al.,
20210)), 5:417K (61) 5:417I (7.1 (Wang et al., 2021c)), 5:417V (26 (I nomson et al.,
(107), (107) , $($	1 al., 2021; 1aua
Copin et al. 2021a, Wang et al., 2021a, Tablet al., 2021a), 5.4551 (4.0 (Da	$(A_{1} \text{ ot al.}, 2020)$
Copin et al., 2021), $5.475K (542 (Wang et al., 2021a)), 5.464K (5Liu et al. 2021: Tada et al. 2022a)) 5.484K (53 (Baum et al. 2020))$	(All et al., 2022, Du et al., 2022;
Tada et al. 2021 , Tada et al. $2022a$), 5.404 (55 (Badin et al., 2020), Tada et al. $2021a$: Tada et al. $2021b$: Tada et al. $2022b$: Wang et al.	al 2021d: Yuan
(a + a) = 2021a) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2021b) S(484O (19 (D)) et al = 2022) Tada et al = 2022b) S(480 et al = 2022b) et al = 2022b) S(480 et al = 2022b) et al = 2022b) S(480 et al = 2022b) et al = 202b) et al = 202b) et al = 202b) et al = 202	6K (> 938 (Starr
(1, 2021), (3.1012) (1) (1) (1) (2022) , 1 and $(1, 20210)$, $(3.40)et al. 2021) S:486L (61 (Conin et al. 2021) Wang et al. 2021c)$	S-486R (>10 000
(Wang et al., 2021a), S:486S (>269 (Tada et al., 2021a)), S:486V (>4)	39 (Copin et al
2021; Wang et al., 2022a)), S:487R (>10,000 (Wang et al., 2021a)), S:4	493E (446 (FDA)

	2022)), S:493K (>438 (Baum et al., 2020; FDA, 2022; Nabel et al., 2022; Tada et al.,
	2022a)), S:493R (42 (Ai et al., 2022; Du et al., 2022; Liu et al., 2021; Nabel et al.,
	2022))
imdevimab	S:371F (87 (Ai et al., 2022; Iketani et al., 2022; Zhou et al., 2022)), S:371L (12 (Ai
	et al., 2022; Liu et al., 2021; Tada et al., 2022a; Wang et al., 2022c)), S:373P (5.9
	(Tada et al., 2022a)), S:406W (108 b (Starr et al., 2021)), S:439K (28 (FDA, 2022)),
	S:440K (9.9 (Wang et al., 2022c)), S:444L (153 (FDA, 2022)), S:444M (>1000 (FDA,
	2022)), S:444N (>755 (FDA, 2022)), S:444Q (>857 (FDA, 2022)), S:444T (>1000
	(FDA, 2022)), S:445A (548 (FDA, 2022)), S: 446S (sw1q574 (Wang et al., 2022c)),
	S:446V (135 (FDA, 2022)), S:450D (9 (FDA, 2022)), S:498H (17 (FDA, 2022)),
	S:498R (3 (Ai et al., 2022)), S:499S (206 (FDA, 2022))
bamlanivimab	S:452R (>1000 (Wang et al., 2021a; Wang et al., 2022a)), S:484A (>357 (Zhou et
	al., 2021)), S: 484D (>100 (FDA)), S: 484K (>1000 (Annavajhala et al., 2021)),
	S:484Q (>100 (Gottlieb et al., 2021)), S:486R (166 (Wang et al., 2021a)), S:486V
	(490 (Wang et al., 2022a)), S:490L (>1000 (Wang et al., 2022a)), S:490S (>100
	(Gottlieb et al., 2021)), S:493H (14 (EMA, 2021)), S:493K (>357 (Nabel et al.,
	2022)), S:493L (9.9 (EMA, 2021)), S: 493R (>1000 (EMA, 2021; Nabel et al.,
	2022)), S: 494P (>100 (EMA, 2021; Gottlieb et al., 2021)), S:494R (>1000 (Wang et
	al., 2021a))
etesevimab	S:371F (143 (Ai et al., 2022)), S:371L (19 (Ai et al., 2022)), S:417N (>227), S:417T
	(>49 (Wang et al., 2021c)), S:420N (>21 (EMA, 2021)), S:456A (15 (Greaney et al.,
	2021)), S:456K (>33 (Greaney et al., 2021)), S:456R (>382 (Wang et al., 2021a)),
	S:460K (>100 (EMA, 2021)), S:460S (>100 (EMA, 2021)), S:460T (>100 (EMA,
	2021)), S:460Y (>132 (EMA, 2021)), S:475R (>382 (Wang et al., 2021a)), S:475V
	(17(Yi, 2020)), S:486L (7 (Wang et al., 2021c; Yi et al., 2021)), S:486R (18(Wang et
	al., 2021a)), S:486V (11 (Wang et al., 2022a)), S:487R (>382 (Wang et al.,
	2021a)), S:493K (27 (Nabel et al., 2022)), S:493L (3.3 (EMA, 2021)), S: 493R (44 (Ai
	et al., 2022; EMA, 2021; Nabel et al., 2022)),)
regdanvimab	S: 452R (35 (Ryu et al., 2021)), S:484K (8.7 (Ryu et al., 2021)), S:493R (> 949 (Ai et
	al., 2022))

mAb(s)	N (of n) cases	SARS-CoV-2 strain	Spike mutations	Ref
	7 out of 101 (6.9%) immunocompetent patients	n.a.	E484K/Q, S494P	Choudhary <i>et al</i> (Boucau et al., 2022; Choudhary et al., 2022)
	1 immunocompromised patient	Alpha	E484K, Q493R	Truffot <i>et al</i> (Truffot et al., 2021)
	1 immunocompromised patient	Alpha	E484K, Q493R, S494P	Lohr <i>et al</i> (Lohr et al., 2021)
	5 out of 6 (83.3%) immunocompromised patients	$\begin{array}{c} E484K \rightarrow \!\!E484Q,\\ B.1 & reverted to E484K\\ & after CCP \end{array}$		Jensen <i>et al</i> (Jensen et al., 2021)
	1 immunocompromised patient	Alpha	E484Q	Bronstein <i>et al</i> (Bronstein et al., 2021)
bamlanivimab	2 immunocompromised patients	20B/20G	E484Q/K	Simons <i>et al</i> (Simons et al., 2022)
monotherapy (700 mg iv)	1 immunocompetent patient	B.1.311	E484K	Sabin <i>et al</i> (Sabin et al., 2022)
	1 immunocompromised patient	B.1.2	E484T	Halfmann <i>et al</i> (Halfmann et al., 2022)
	2 immunocompromised patients	20A.EU2 / 20I/501Y.V1	E484A/K	Destras <i>et al</i> (Destras et al., 2021)
	2 immunocompromised patients		E484Q/K, Q493R	Scherer et al (Scherer et al., 2022)
	5 out of 45 (11.1%)	Alpha	E484A/K, Q493R, S494P	Gupta <i>et al</i> (Gupta et al., 2023)
	1 out of 2 (50%) immunocompetent	B.1.214.2 Alpha	Q493R	Jary <i>et al</i> (Jary et al., 2022)
	5 out of 6 (83.3%)	Alpha	E484A/K, Q493R, S494P	Peiffer-Smadja <i>et al</i> (Peiffer-Smadja et al., 2021)
	1 out of 102 (1%) patients	В.*	S494P	Gottlieb <i>et al</i> (Gottlieb et al., 2021)
	1 immunocompromised patient		Q493R	Focosi <i>et al</i> (Focosi et al., 2021)
bamlanivimab 700 mg + etesevimab 1400 mg cocktail	1 immunocompromised patient	Alpha	Q493R	Guigon <i>et al</i> (Guigon et al., 2021)
	5 out of 23 (21.7%) patients (17 immunocompromised)		E484K, Q493R	Vellas <i>et al</i> (Vellas et al., 2021)
	3 out of 108 (2.8%)		E484D, Q493R/K	Gupta <i>et al</i> (Gupta et al., 2023)
	1 out of 3 (33%)		Q493R	Jary et al (Jary et al., 2022)
	5 out of 34 (14.7) patients		Q493R, E484D	Pommeret <i>et al</i>

Table 2. Published reports of anti-Spike mAb treatment-emergent resistance

	(5 with B-cell malignancies)			(Pommeret et al., 2021)
casirivimab + imdevimab (REGN-CoV)	1 immunocompromised patient	n.a.	E484K/A, Y489H, Q493K and N501Y	Choi <i>et al</i> (Choi et al., 2020) Clarke <i>et al</i> (Clark et al., 2021)
	0 out of 8 (0%)	Alpha (7) and Gamma (1)	-	Jary <i>et al</i> (Jary et al., 2022)
cocktail	1 out of 17 (5.9%)	Alpha	E406G	Gupta <i>et al</i> (Gupta et al., 2023)
	15 out of 160 (9.4%)	Delta, BA.1	E406D/Q, G446S/V, Y453F, L455F/S	Ragonnet-Cronin <i>et al</i> (Ragonnet-Cronin et al., 2022)
	4 cases out of 100 (4%)	Delta	E340K/A/V	Rockett <i>et al</i> (Rockett et al., 2021)
	10 cases out of 18 (55.6%) (15 immunocompromised)	BA.1 (94%) BA.2 (6%)	E340K/A/V/D/G/Q, P337L/R/S	Birnie <i>et al</i> (Birnie et al., 2022)
sotrovimab	3 out of 16 (18.8%) immunocompromised patients	2 BA.1, 1 BA.2	E340D	Focosi <i>et al</i> (Focosi et al., 2022b)
	18 out of 34 (52.9%) immunocompromised patients	17 BA.1 1 BA.2	P337L/S, E340A/K/D/G, K356T, S371F	Vellas <i>et al</i> (Vellas et al., 2022b)
	4 of 25 (16%) BA.1-infected patients 2 of 7 (28.6%) BA.2- infected	BA.1 BA.2	P337X, E340X	Huygens <i>et al</i> (Huygens et al., 2022)
	5 out of 8 (62.5%) immunocompromised	BA.1 (7) AY.100 (1)	P337L, E340D/R/K/V/Q, R346T, K356T	Andrés <i>et al</i> (Andrés et al., 2023)
	8 patients	BA.1	P337R/S, E340A/D/K/Q	Destras <i>et al</i> (Destras et al., 2022)
	9 out of 34 (26.5%)	BA.1.1.* (n=14) BA.1 (n = 13) BA.2 (n = 7)	E340K/D/V	Gupta <i>et al</i> (Gupta et al., 2023)
	54 out of 134 (40.3%) patients	Delta, BA.1, BA.2	P337R/S, E340A/D/K/V, K356T	Ragonnet-Cronin <i>et al</i> (Ragonnet-Cronin et al., 2022)
	14 out of 43 (32.6%) patients	BA.1	P337S/H/L/R, E340K/D/V	Gliga <i>et al</i> (Gliga et al., 2022)
cilgavimab-	9 out of 18 (50%) immunocompromised cases	BA.2	K444R/N, R346T, L452M	Vellas <i>et al</i> (Vellas et al., 2022a)
tixagevimab	1 out 19 (5.3%) immunocompetent cases	BA.4/5	K444N	Maggi <i>et al</i> (Fabeni et al., 2023)

bebtelovimab	1 immunocompromised patient	BA.1.23	V445A	Gonzalez-Reiche <i>et al</i> (Gonzalez-Reiche et al., 2022)
--------------	-----------------------------	---------	-------	---

Table 3. Frequencies of treatment-emergentresistand

mAb (n=number of	# of	patients	total # (of pa	tients	percent	of	number	of
cohort series)	developing		across	all	case	patients		additional	
	treatment-		series			developing		single	case
	emergent					treatment-		reports	
	resistance					emergent			
	mutations	across				resistance	across		
	all case seri	es				all case seri	es		
bamlanivimab (n=5)		23			160		14.4%		11
bamlanivimab+									2
etesevimab (n=5)		15			270		5.6%		
casirivimab+									1
imdevimab (n=3)		16			185		8.6%		
sotrovimab (n=11)		131			427		30.7%		0
cilgavimab-									0
tixagevimab (n=2)		10			37		27.0%		
bebtelovimab (n=0)		n.a.			n.a.		n.a.		1
Total		195			1079		18.1		15

References

ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2. Accessed online at <u>https://www.ema.europa.eu/en/news/etf-warns-monoclonal-antibodies-may-not-be-effective-against-emerging-strains-sars-cov-2 on January 24, 2023.</u>

Fact sheet for healthcare providers emergency use authorization (EUA) of sotrovimab. Accessed online at <u>https://www.fda.gov/media/149534/download</u> on February 22, 2023.

Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. Accessed online at <u>https://www.fda.gov/media/156152/download</u> on February 21, 2022.

FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization. Accessed online at https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclonal-antibody-products-

<u>under#:~:text=Today%2C%20the%20U.S.%20Food%20and,for%20the%20treatment%20of%20COVID%2</u> <u>D</u> on February 22, 2023.

Regeneron Ireland DAC use of casirivimab and imdevimab for the treatment of COVID-19.

J. Ai, X. Wang, X. He, X. Zhao, Y. Zhang, Y. Jiang, M. Li, Y. Cui, Y. Chen, R. Qiao, L. Li, L. Yang, Y. Li, Z. Hu, W. Zhang and P. Wang, Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages, *Cell host & microbe* **30** (2022), pp. 1077-1083.e1074.

T.S. Anderson, A. O'Donoghue, O. Mechanic, T. Dechen and J. Stevens, Administration of Anti–SARS-CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization, *JAMA Network Open* **5** (2022), pp. e2228997-e2228997.

C. Andrés, A. González-Sánchez, M. Jiménez, E. Márquez-Algaba, M. Piñana, C. Fernández-Naval, J. Esperalba, N. Saubi, J. Quer, A. Rando-Segura, M. Miarons, M.G. Codina, I. Ruiz-Camps, T. Pumarola, P. Abrisqueta and A. Antón, Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with long-term viral excretion, *Clinical Microbiology and Infection* **29** (2023), pp. 240-246.

M.K. Annavajhala, H. Mohri, P. Wang, M. Nair, J.E. Zucker, Z. Sheng, A. Gomez-Simmonds, A.L. Kelley, M. Tagliavia, Y. Huang, T. Bedford, D.D. Ho and A.-C. Uhlemann, Emergence and expansion of SARS-CoV-2 B.1.526 after identification in New York, *Nature* **597** (2021), pp. 703-708.

A. Baum, B.O. Fulton, E. Wloga, R. Copin, K.E. Pascal, V. Russo, S. Giordano, K. Lanza, N. Negron, M. Ni, Y. Wei, G.S. Atwal, A.J. Murphy, N. Stahl, G.D. Yancopoulos and C.A. Kyratsous, Antibody cocktail to SARS-CoV-2 spike protein prevents rapid mutational escape seen with individual antibodies, **369** (2020), pp. 1014-1018.

E. Birnie, J.J. Biemond, B. Appelman, G.J. de Bree, M. Jonges, M.R.A. Welkers and W.J. Wiersinga, Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Individuals Infected With the SARS-CoV-2 Omicron Variant, *Jama* **328** (2022), pp. 1104-1107.

J. Boucau, K.W. Chew, M.C. Choudhary, R. Deo, J. Regan, J.P. Flynn, C.R. Crain, M.D. Hughes, J. Ritz, C. Moser, J.A. Dragavon, A.C. Javan, A. Nirula, P. Klekotka, A.L. Greninger, R.W. Coombs, W.A. Fischer, E.S. Daar, D.A. Wohl, J.J. Eron, J.S. Currier, D.M. Smith, J.Z. Li and A.K. Barczak, Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection, *Cell Reports Medicine* **3** (2022), p. 100678.

Y. Bronstein, A. Adler, H. Katash, O. Halutz, H. Y and K. Levytskyi, Evolution of spike mutations following antibody treatment in two immunocompromised patients with persistent COVID-19 infection, *Journal of medical virology* (2021).

Y. Cao, F. Jian, J. Wang, Y. Yu, W. Song, A. Yisimayi, J. Wang, R. An, N. Zhang, Y. Wang, P. Wang, L. Zhao, H. Sun, L. Yu, S. Yang, X. Niu, T. Xiao, Q. Gu, F. Shao, X. Hao, Y. Xu, R. Jin, Y. Wang and X.S. Xie, Imprinted

SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution, *Nature* (2022), p. 2022.2009.2015.507787.

A. Casadevall and D. Focosi, SARS-CoV-2 variants resistant to monoclonal antibodies in immunocompromised patients is a public health concern, *The Journal of clinical investigation* (2023).
A.L. Cathcart, C. Havenar-Daughton, F.A. Lempp, D. Ma, M. Schmid, M.L. Agostini, B. Guarino, J. Di iulio, L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, J. Zhou, H. Kaiser, A. Chase, M. Montiel-Ruiz, N. Czudnochowski, E. Cameroni, S. Ledoux, C. Colas, L. Soriaga, A. Telenti, S. Hwang, G. Snell, H.W. Virgin, D. Corti and C.M. Hebner, The dual function monoclonal antibodies VIR-7831 and VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2, (2021), p. 2021.2003.2009.434607.

C. Chen, S. Nadeau, M. Yared, P. Voinov, N. Xie, C. Roemer and T. Stadler, CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants, *Bioinformatics* **38** (2021a), pp. 1735-1737.

R.E. Chen, X. Zhang, J.B. Case, E.S. Winkler, Y. Liu, L.A. VanBlargan, J. Liu, J.M. Errico, X. Xie, N. Suryadevara, P. Gilchuk, S.J. Zost, S. Tahan, L. Droit, J.S. Turner, W. Kim, A.J. Schmitz, M. Thapa, D. Wang, A.C.M. Boon, R.M. Presti, J.A. O'Halloran, A.H.J. Kim, P. Deepak, D. Pinto, D.H. Fremont, J.E. Crowe, Jr., D. Corti, H.W. Virgin, A.H. Ellebedy, P.Y. Shi and M.S. Diamond, Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies, *Nat Med* **27** (2021b), pp. 717-726.

B. Choi, M.C. Choudhary, J. Regan, J.A. Sparks, R.F. Padera, X. Qiu, I.H. Solomon, H.-H. Kuo, J. Boucau, K.
Bowman, U.D. Adhikari, M.L. Winkler, A.A. Mueller, T.Y.-T. Hsu, M. Desjardins, L.R. Baden, B.T. Chan, B.D.
Walker, M. Lichterfeld, M. Brigl, D.S. Kwon, S. Kanjilal, E.T. Richardson, A.H. Jonsson, G. Alter, A.K.
Barczak, W.P. Hanage, X.G. Yu, G.D. Gaiha, M.S. Seaman, M. Cernadas and J.Z. Li, Persistence and
Evolution of SARS-CoV-2 in an Immunocompromised Host, **383** (2020), pp. 2291-2293.
M.C. Choudhary, K.W. Chew, R. Deo, J.P. Flynn, J. Regan, C.R. Crain, C. Moser, M.D. Hughes, J. Ritz, R.M.
Ribeiro, R. Ke, J.A. Dragavon, A.C. Javan, A. Nirula, P. Klekotka, A.L. Greninger, C.V. Fletcher, E.S. Daar,
D.A. Wohl, J.J. Eron, J.S. Currier, U.M. Parikh, S.F. Sieg, A.S. Perelson, R.W. Coombs, D.M. Smith, J.Z. Li, D.
Smith, A.C. Javan, M. Giganti, L. Hosey, J. Roa, N. Patel, K. Colsh, I. Rwakazina, J. Beck, S. Sieg, W. Fischer,
T. Evering, R.B. Ignacio, S. Cardoso, K. Corado, P. Jagannathan, N. Jilg, S. Pillay, C. Riviere, U. Singh, B.
Taiwo, J. Gottesman, M. Newell, S. Pedersen, J. Dragavon, C. Jennings, B. Greenfelder, W. Murtaugh, J.
Kosmyna, M. Gapara, A. Shahkolahi and A.-A.S.T. for the, Emergence of SARS-CoV-2 escape mutations
during Bamlanivimab therapy in a phase II randomized clinical trial, *Nature Microbiology* 7 (2022), pp.

S.A. Clark, L.E. Clark, J. Pan, A. Coscia, L.G.A. McKay, S. Shankar, R.I. Johnson, V. Brusic, M.C. Choudhary, J. Regan, J.Z. Li, A. Griffiths and J. Abraham, SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms, *Cell* **184** (2021), pp. 2605-2617.e2618.

1906-1917.

R. Copin, A. Baum, E. Wloga, K.E. Pascal, S. Giordano, B.O. Fulton, A. Zhou, N. Negron, K. Lanza, N. Chan, A. Coppola, J. Chiu, M. Ni, G.S. Atwal, A. Romero Hernandez, K. Saotome, Y. Zhou, M.C. Franklin, A.T. Hooper, S. McCarthy, S. Hamon, J.D. Hamilton, H.M. Staples, K. Alfson, R. Carrion, S. Ali, T. Norton, S. Somersan-Karakaya, S. Sivapalasingam, G.A. Herman, D.M. Weinreich, L. Lipsich, N. Stahl, A.J. Murphy, G.D. Yancopoulos and C.A. Kyratsous, The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies, *Cell* **184** (2021), pp. 3949-3961. G. Destras, S. Assaad, A. Bal, M. Bouscambert-Duchamp, V. Avrillon, B. Simon, M. Valette, J.-Y. Blay, B. Lina, E. Frobert and L. Josset, Bamlanivimab as monotherapy in two immunocompromised patients with COVID-19, *The Lancet Microbe* **2** (2021), p. e424.

G. Destras, A. Bal, B. Simon, B. Lina and L. Josset, Sotrovimab drives SARS-CoV-2 Omicron variant evolution in immunocompromised patients, *The Lancet. Microbe* **3** (2022), p. E559.

W. Du, D.L. Hurdiss, D. Drabek, A.Z. Mykytyn, F. Kaiser, M. Gonzalez-Hernandez, D. Munoz-Santos, M.M. Lamers, R. van Haperen, W. Li, I. Drulyte, C. Wang, I. Sola, F. Armando, G. Beythien, M. Ciurkiewicz, W. Baumgartner, K. Guilfoyle, T. Smits, J. van der Lee, F.J.M. van Kuppeveld, G. van Amerongen, B.L. Haagmans, L. Enjuanes, A.D. Osterhaus, F. Grosveld and B.J. Bosch, An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants, (2022), p. 2022.2002.2017.480751.

EMA, Eli Lilly and Company Limited use of bamlanivimab and etesevimab for the treatment of COVID-19, (2021).

L. Fabeni, C.E. Gruber, F. Tucci, V. Mazzotta, M. Rueca, G. Gramigna, A. Vergori, E. Giombini, O. Butera, D. Focosi, E. Nicastri, E. Girardi, F. Vaia, A. Antinori and F. Maggi, Treatment-emergent cilgavimab resistance in Omicron BA.4/5, *Drug Resistance Updates* (2023).

FDA, Fact sheet for healthcare providers: emergency use authorization for Evusheld[™] (tixagevimab copackaged with cilgavimab). Accessed online at <u>https://www.fda.gov/media/154701/download</u> on February 3, 2023, (2021).

FDA, FDA authorizes revisions to Evusheld dosing. Accessed online on April 29, 2022 at https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing, (2022).

FDA, FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody products under emergency use authorization. Accessed online at https://www.fda.gov/drugs

D. Focosi, A web tool to estimate baaseline anti-Spike monoclonal antibody efficacy based on regional genomic surveillance, *submitted* (2023).

D. Focosi, S. McConnell, A. Casadevall, E. Cappello, G. Valdiserra and M. Tuccori, Monoclonal antibody therapies against SARS-CoV-2, *The Lancet Infectious Diseases* **22** (2022a), pp. 00311-00315.

D. Focosi, F. Novazzi, A. Baj, F.D. Ferrante, S. Boutahar, A.P. Genoni, D.D. Gasperina and F. Maggi, Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases, *J Clin Virol Plus* **2** (2022b), p. 100097.

D. Focosi, F. Novazzi, A. Genoni, F. Dentali, D. Dalla Gasperina, A. Baj and F. Maggi, Daniele Focosi, Federica Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla gasperina, Andreina Baj, Fabrizio Maggi, (2021).

D. Focosi, R. Quiroga, S. McConnell, M.C. Johnson and A. Casadevall, Convergent evolution in SARS-CoV-2 Spike creates a variant soup from which new COVID-19 waves emerge, *International Journal of Molecular Sciences* **24** (2023), p. 2264.

D. Focosi and M. Tuccori, Prescription of Anti-Spike Monoclonal Antibodies in COVID-19 Patients with Resistant SARS-CoV-2 Variants in Italy, *Pathogens (Basel, Switzerland)* **11** (2022).

S. Gliga, N. Luebke, A. Killer, H. Gruell, A. Walker, A.T. Dilthey, C. Lohr, C. Flaßhove, H.M. Orth, T. Feldt, J.G. Bode, F. Klein, J. Timm, T. Luedde and B.O. Jensen, Rapid selection of sotrovimab escape variants in SARS-CoV-2 Omicron infected immunocompromised patients, *Clinical Infectious Diseases* (2022).

R.L. Gottlieb, A. Nirula, P. Chen, J. Boscia, B. Heller, J. Morris, G. Huhn, J. Cardona, B. Mocherla, V. Stosor, I. Shawa, P. Kumar, A.C. Adams, J. Van Naarden, K.L. Custer, M. Durante, G. Oakley, A.E. Schade, T.R.

Holzer, P.J. Ebert, R.E. Higgs, N.L. Kallewaard, J. Sabo, D.R. Patel, P. Klekotka, L. Shen and D.M. Skovronsky, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load

in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, *JAMA* **325** (2021), pp. 632-644. A.J. Greaney, A.N. Loes, K.H. Crawford, T.N. Starr, K.D. Malone, H.Y. Chu and J.D. Bloom, Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies, *bioRxiv* [*Preprint*] (2021).

A. Guigon, E. Faure, C. Lemaire, M. Chopin, C. Tinez, A. Assaf, M. Lazrek, D. Hober, L. Bocket, I. Engelmann and E. Kazali Alidjinou, Emergence of Q493R mutation in SARS-CoV-2 spike protein during bamlanivimab/etesevimab treatment and resistance to viral clearance, *J Infect* **S0163-4453** (2021), pp. 00435-00437.

A. Gupta, A. Konnova, M. Smet, M. Berkell, A. Savoldi, M. Morra, V. Van Averbeke, F. De Winter, D. Peserico, E. Danese, A. Hotterbeekx, E. Righi, m.O.w. group, P. De Nardo, E. Tacconellil, S. Malhotra-Kumar and S. Kumar-Singh, Host immunological responses facilitate development of SARS-CoV-2 2 mutations in patients receiving monoclonal antibody treatments, *The Journal of clinical investigation* (2023).

P.J. Halfmann, N.R. Minor, L.A. Haddock III, R. Maddox, G.K. Moreno, K.M. Braun, D.A. Baker, K.K. Riemersa, A. Prasad, K.J. Alman, M.C. Lambert, K. Florek, A. Bateman, R. Westergaard, N. Safdar, D.R. Andes, Y. Kawaoka, M. Fida, J.D. Yao, T.C. Friedrich and D.H. O'Connor, Evolution of a globally unique SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected, immunocompromised individual, *Virus Evolution* (2022).

K. Harman, S.G. Nash, H.H. Webster, N. Groves, J. Hardstaff, J. Bridgen, P.B. Blomquist, R. Hope, E. Ashano, R. Myers, S. Rokadiya, S. Hopkins, C.S. Brown, M. Chand, G. Dabrera and S. Thelwall, Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab in the community in England, (2022), p. 2022.2010.2021.22281171.

M. Hoffmann, L. Zhang, N. Krüger, L. Graichen, H. Kleine-Weber, H. Hofmann-Winkler, A. Kempf, S. Nessler, J. Riggert, M.S. Winkler, S. Schulz, H.-M. Jäck and S. Pöhlmann, SARS-CoV-2 mutations acquired in mink reduce antibody-mediated neutralization, (2021), p. 2021.2002.2012.430998.

R.V. House, T.A. Broge, T.J. Suscovich, D.M. Snow, M.T. Tomic, G. Nonet, K. Bajwa, G. Zhu, Z. Martinez, K. Hackett, C.G. Earnhart, N.M. Dorsey, S.A. Hopkins, D.S. Natour, H.D. Davis, M.S. Anderson, M.R. Gainey and R.R. Cobb, Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal functionality as therapeutics, *PloS one* **17** (2022), p. e0267796.

S. Huygens, B.O. Munnink, A. Gharbharan, M. Koopmans and B. Rijnders, Sotrovimab resistance and viral persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron variant, *Clinical Infectious Diseases* (2022).

S. Iketani, L. Liu, Y. Guo, L. Liu, Y. Huang, M. Wang, Y. Luo, J. Yu, M.T. Yin, M.E. Sobieszczyk, Y. Huang, H.H. Wang, Z. Sheng and D.D. Ho, Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages, *Nature* **604** (2022), pp. 553-556.

A. Jary, S. Marot, A. Faycal, S. Leon, S. Sayon, K. Zafilaza, E. Ghidaoui, S.N. Quoc, S. Nemlaghi, S. Choquet, M. Dres, V. Pourcher, V. Calvez, H. Junot, A.G. Marcelin and C. Soulié, Spike Gene Evolution and Immune Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal Antibodies Therapies, *Viruses* **14** (2022).

B. Jensen, N. Luebke, T. Feldt, V. Keitel, T. Brandenburger, D. Kindgen-Milles, M. Lutterbeck, N.F. Freise, D. Schoeler, R. Haas, A. Dilthey, O. Adams, A. Walker, J. Timm and T. Luedde, Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany, *The Lancet Regional Health – Europe* **8** (2021).

L. Liu, S. Iketani, Y. Guo, J.F.-W. Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huang, M.S. Nair, J. Yu, K.K.-H. Chik, T.T.-T. Yuen, C. Yoon, K.K.-W. To, H. Chen, M.T. Yin, M.E. Sobieszczyk, Y. Huang, H.H. Wang, Z. Sheng, K.-Y. Yuen and D.D. Ho, Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, (2021), p. 2021.2012.2014.472719.

B. Lohr, D. Niemann and J. Verheyen, Bamlanivimab treatment leads to rapid selection of immune escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient, *Clinical Infectious Diseases* (2021).

K.G. Nabel, S.A. Clark, S. Shankar, J. Pan, L.E. Clark, P. Yang, A. Coscia, L.G.A. McKay, H.H. Varnum, V. Brusic, N.V. Tolan, G. Zhou, M. Desjardins, S.E. Turbett, S. Kanjilal, A.C. Sherman, A. Dighe, R.C. LaRocque,

E.T. Ryan, C. Tylek, J.F. Cohen-Solal, A.T. Darcy, D. Tavella, A. Clabbers, Y. Fan, A. Griffiths, I.R. Correia, J. Seagal, L.R. Baden, R.C. Charles and J. Abraham, Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain, **375** (2022), p. eabl6251.

V. Patel, B. Levick, S. Boult, D.C. Gibbons, M. Drysdale, E.J. Lloyd, M. Singh and H.J. Birch, Characteristics and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in England, (2023), p. 2023.2002.2008.23285654.

N. Peiffer-Smadja, A. Bridier-Nahmias, V.M. Ferré, C. Charpentier, M. Garé, C. Rioux, A. Allemand, P. Lavallée, J. Ghosn, L. Kramer, D. Descamps, Y. Yazdanpanah and B. Visseaux, Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2, *Viruses* **13** (2021).

F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, A. Bayle, J.M. Michot, T. Hueso, L. Albiges, P. Tiberghien, S. Marot, A. Jary, K. Lacombe, F. Barlesi, F. Griscelli and E. Colomba, Bamlanivimab+ etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration in COVID-19 patients with B-cell malignancies, *Annals of Oncology* (2021).

M. Ragonnet-Cronin, R. Nutalai, J. Huo, A. Dijokaite-Guraliuc, R. Das, A. Tuekprakhon, P. Supasa, C. Liu, M. Selvaraj, N. Groves, H. Hartman, N. Ellaby, J.M. Sutton, M.W. Bahar, D. Zhou, E. Fry, J. Ren, C. Brown, P. Klenerman, S.J. Dunachie, J. Mongkolsapaya, S. Hopkins, M. Chand, D.I. Stuart, G.R. Screaton and S. Rokadiya, Genome-first detection of emerging resistance to novel therapeutic agents for SARS-CoV-2, *bioRxiv* (2022), p. 2022.2007.2014.500063.

R.J. Rockett, K. Basile, S. Maddocks, W. Fong, J.E. Agius, J. Johnson-Mackinnon, A. Arnott, S. Chandra, M. Gall, J.L. Draper, E. Martinez, E.M. Sim, C. Lee, C. Ngo, M. Ramsperger, A.N. Ginn, Q. Wang, M. Fennell, D. Ko, L. Lim, N. Gilroy, M.V. Sullivan, S.C.-A. Chen, J. Kok, D.E. Dwyer and V.L. Sintchenko, Resistance mutations in SARS-CoV-2 Delta variant after sotrovimab use, *N Engl J Med* **386** (2021), pp. 1477-1479. D.-K. Ryu, H.-M. Woo, B. Kang, H. Noh, J.-I. Kim, J.-M. Seo, C. Kim, M. Kim, J.-W. Kim, N. Kim, P. Jeon, H. Lee, J.-S. Yang, K.-C. Kim, J.-Y. Lee, M.-H. Lee, S.-S. Oh, H.-Y. Chung, K.-S. Kwon and S.-Y. Lee, The in vitro and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2, (2021), p. 2021.2007.2023.453472.

A.P. Sabin, C.S. Richmond and P.A. Kenny, Emergence and onward transmission of a SARS-CoV-2 E484K variant among household contacts of a bamlanivimab-treated patient., *Diagn Microbiol Infect Dis* **103** (2022), p. 115656.

E.M. Scherer, A. Babiker, M.W. Adelman, B. Allman, A. Key, J.M. Kleinhenz, R.M. Langsjoen, P.-V. Nguyen, I. Onyechi, J.D. Sherman, T.W. Simon, H. Soloff, J. Tarabay, J. Varkey, A.S. Webster, D. Weiskopf, D.B. Weissman, Y. Xu, J.J. Waggoner, K. Koelle, N. Rouphael, S.M. Pouch and A. Piantadosi, SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Patients, **386** (2022), pp. 2436-2438.

L.M. Simons, E.A. Ozer, S. Gambut, T.J. Dean, L. Zhang, P. Bhimalli, J.R. Schneider, J.I. Mamede, M.G. Ison, R. Karmali, L.I. Gordon, R. Lorenzo-Redondo and J.F. Hultquist, De novo emergence of SARS-CoV-2 spike mutations in immunosuppressed patients, *Transplant infectious disease : an official journal of the Transplantation Society* **24** (2022), p. e13914.

E. Stadler, M.T. Burgess, T.E. Schlub, K.L. Chai, Z.K. McQuilten, E.M. Wood, M.N. Polizzotto, S.J. Kent, D. Cromer, M.P. Davenport and D.S. Khoury, Monoclonal antibody levels and protection from COVID-19, (2022a), p. 2022.2011.2022.22282199.

E. Stadler, K.L. Chai, T.E. Schlub, D. Cromer, M.N. Polizzotto, S.J. Kent, C. Beecher, H. White, T. Turner, N. Skoetz, L. Estcourt, Z.K. McQuilten, E.M. Wood, D.S. Khoury and M.P. Davenport, Determinants of passive antibody efficacy in SARS-CoV-2 infection, (2022b), p. 2022.2003.2021.22272672.

T.N. Starr, A.J. Greaney, A. Addetia, W.W. Hannon, M.C. Choudhary, A.S. Dingens, J.Z. Li and J.D. Bloom, Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, *Science* (2021), p. eabf9302.

T. Tada, B.M. Dcosta, M.I. Samanovic, R.S. Herati, A. Cornelius, H. Zhou, A. Vaill, W. Kazmierski, M.J. Mulligan and N.R. Landau, Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes, *mBio* **12** (2021a), p. e0069621.

T. Tada, H. Zhou, B.M. Dcosta, M.I. Samanovic, V. Chivukula, R. Herati, S.R. Hubbard, M.J. Mulligan and N.R. Landau, Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited and Therapeutic Antibodies, *EBioMedicine* (2022a), p. 2021.2012.2028.474369.

T. Tada, H. Zhou, B.M. Dcosta, M.I. Samanovic, M.J. Mulligan and N.R. Landau, Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera, *iScience* (2021b).

T. Tada, H. Zhou, M.I. Samanovic, B.M. Dcosta, A. Cornelius, R.S. Herati, M.J. Mulligan and N.R. Landau, Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies, *Frontiers in immunology* **13** (2022b), p. 797589.

E.C. Thomson, L.E. Rosen, J.G. Shepherd, R. Spreafico, A. da Silva Filipe, J.A. Wojcechowskyj, C. Davis, L. Piccoli, D.J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, A. De Marco, K. Li, J. Bassi, A. O'Toole, D. Pinto, R.M. Colquhoun, K. Culap, B. Jackson, F. Zatta, A. Rambaut, S. Jaconi, V.B. Sreenu, J. Nix, R.F. Jarrett, M. Beltramello, K. Nomikou, M. Pizzuto, L. Tong, E. Cameroni, N. Johnson, A. Wickenhagen, A. Ceschi, D. Mair, P. Ferrari, K. Smollett, F. Sallusto, S. Carmichael, C. Garzoni, J. Nichols, M. Galli, J. Hughes, A. Riva, A. Ho, M.G. Semple, P.J.M. Openshaw, J.K. Baillie, S.J. Rihn, S.J. Lycett, H.W. Virgin, A. Telenti, D. Corti, D.L. Robertson and G. Snell, The circulating SARS-CoV-2 spike variant N439K maintains fitness while evading antibody-mediated immunity, (2020), p. 2020.2011.2004.355842.

A. Truffot, J. Andreani, M. Le Marechal, A. Caporossi, O. Epaulard, P. Poignard and L. Sylvie, SARS-CoV-2 Variants in Immunocompromised Patient Given Antibody Monotherapy, *Emerging infectious diseases* **27** (2021).

P.L. Tzou, K. Tao, J. Nouhin, S.-Y. Rhee, B.D. Hu, S. Pai, N. Parkin and R.W. Shafer, Coronavirus Antiviral Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between Candidate Anti-Coronavirus Compounds, **12** (2020), p. 1006.

C. Vellas, A. Del Bello, D. Alexa, Z. Steinmeyer, L. Tribaudeau, N. Ranger, N. Jeanne, G. Martin-Blondel, P. Delobel, N. Kamar and J. Izopet, Influence of neutralizing monoclonal antibodies on the SARS-CoV-2 quasispecies in patients with COVID-19, *Clin Microb Infect* (2021).

C. Vellas, N. Kamar and J. Izopet, Resistance mutations in SARS-CoV-2 Omicron variant after tixagevimab-cilgavimab treatment, *Journal of Infection* **85** (2022a), pp. e162-e163.

C. Vellas, P. Trémeaux, A. Del Bello, J. Latour, N. Jeanne, N. Ranger, C. Danet, G. Martin-Blondel, P. Delobel, N. Kamar and J. Izopet, Resistance mutations in SARS-CoV-2 Omicron variant in patients treated with sotrovimab, *Clinical Microbiology and Infection* **28** (2022b), pp. 1297-1299.

L. Wang, T. Zhou, Y. Zhang, E.S. Yang, C.A. Schramm, W. Shi, A. Pegu, O.K. Oloniniyi, A.R. Henry, S. Darko, S.R. Narpala, C. Hatcher, D.R. Martinez, Y. Tsybovsky, E. Phung, O.M. Abiona, A. Antia, E.M. Cale, L.A. Chang, M. Choe, K.S. Corbett, R.L. Davis, A.T. DiPiazza, I.J. Gordon, S.H. Hait, T. Hermanus, P. Kgagudi, F. Laboune, K. Leung, T. Liu, R.D. Mason, A.F. Nazzari, L. Novik, S. O'Connell, S. O'Dell, A.S. Olia, S.D. Schmidt, T. Stephens, C.D. Stringham, C.A. Talana, I.-T. Teng, D.A. Wagner, A.T. Widge, B. Zhang, M. Roederer, J.E. Ledgerwood, T.J. Ruckwardt, M.R. Gaudinski, P.L. Moore, N.A. Doria-Rose, R.S. Baric, B.S. Graham, A.B. McDermott, D.C. Douek, P.D. Kwong, J.R. Mascola, N.J. Sullivan and J. Misasi, Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants, **373** (2021a), p. eabh1766. P. Wang, M.S. Nair, L. Lihong, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P.D. Kwong, B.S. Graham, J.R. Mascola, J.Y. Chang, M.T. Yin, M.E. Sobieszczyk, C.A. Kyratsous, L. Shapiro, Z. Sheng, Y. Huang and D.D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, *Nature* **593** (2021b), pp. 130-135.

Q. Wang, Y. Guo, S. Iketani, Z. Li, H. Mohri, M. Wang, J. Yu, A.D. Bowen, J.Y. Chan, J.G. Shah, N. Nguyen, K. Meyers, M.T. Yin, M.E. Sobieszczyk, Z. Sheng, Y. Huang, L. Liu and D. Ho, Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5, *Nature* **608** (2022a), pp. 603–608.

Q. Wang, S. Iketani, Z. Li, Y. Guo, A.Y. Yeh, M. Liu, J. Yu, Z. Sheng, Y. Huang, L. Liu and D.D. Ho, Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75, (2022b), p. 2022.2007.2031.502235. R. Wang, Q. Zhang, J. Ge, W. Ren, R. Zhang, J. Lan, B. Ju, B. Su, F. Yu, P. Chen, H. Liao, Y. Feng, X. Li, X. Shi, Z. Zhang, F. Zhang, Q. Ding, T. Zhang, X. Wang and L. Zhang, Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and the ability to use ACE2 receptors from additional species, *Immunity* **54** (2021c), pp. 1611-1621.e1615.

Y. Wang, X. Zhang, J. Liu, Y. Wang, W. Zhan, M. Liu, M. Zhang, Q. Wang, Q. Liu, T. Zhu, Y. Wen, Z. Chen, J. Zhao, F. Wu, L. Sun and J. Huang, Combating the SARS-CoV-2 Omicron variant with non-Omicron neutralizing antibodies, (2022c), p. 2022.2001.2030.478305.

Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C.O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Gaebler, J.A. Lieberman, Z. Yang, M.E. Abernathy, K.E. Huey-Tubman, A. Hurley, M. Turroja, K.A. West, K. Gordon, K.G. Millard, V. Ramos, J.D. Silva, J. Xu, R.A. Colbert, R. Patel, J.P. Dizon, C. Unson-O'Brien, I. Shimeliovich, A. Gazumyan, M. Caskey, P.J. Bjorkman, R. Casellas, T. Hatziioannou, P.D. Bieniasz and M.C. Nussenzweig, mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. *bioRxiv* [Preprint] (2021d), p. 2021.2001.2015.426911.

K. Westendorf, S. Žentelis, D. Foster, P. Vaillancourt, M. Wiggin, E. Lovett, J. Hendle, A. Pustilnik, J.M. Sauder, L. Kraft, Y. Hwang, R.W. Siegel, J. Chen, B.A. Heinz, R.E. Higgs, N. Kalleward, K. Jepson, R. Goya, M.A. Smith, D.W. Collins, D. Pellacani, P. Xiang, V. de Puyraimond, M. Ricicova, L. Devorkin, C. Pritchard, A. O'Neill, C. Cohen, J. Dye, K.I. Huie, C.V. Badger, D. Kobasa, J. Audet, J.J. Freitas, S. Hassanali, I. Hughes, L. Munoz, H.C. Palma, B. Ramamurthy, R.W. Cross, T.W. Geisbert, I. Lanz, L. Anderson, P. Sipahimalani, K.S. Corbett, L. Wang, E.S. Yang, Y. Zhang, W. Shi, B.S. Graham, J.R. Mascola, T.L. Fernandez, C.L. Hansen, E. Falconer, B.E. Jones and B.C. Barnhart, LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants, *Cell Rep* (2022), p. 2021.2004.2030.442182.

M.Y. Wu, E.J. Carr, R. Harvey, H.V. Mears, S. Kjaer, H. Townsley, A. Hobbs, M. Ragno, L.S. Herman, L. Adams, S. Gamblin, M. Howell, R. Beale, M. Brown, B. Williams, S. Gandhi, C. Swanton, E.C. Wall and D.L.V. Bauer, WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed, *Lancet* **400** (2022), pp. 2193-2196.

W. Yao, D. Ma, H. Wang, X. Tang, C. Du, H. Pan, C. Li, H. Lin, M. Farzan, J. Zhao, Y. Li and G. Zhong, Effect of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity, (2021), p. 2021.2001.2027.428353.

C. Yi, X. Sun, Y. Lin, C. Gu, L. Ding, X. Lu, Z. Yang, Y. Zhang, L. Ma, W. Gu, A. Qu, X. Zhou, X. Li, J. Xu, Z. Ling,
Y. Xie, H. Lu and B. Sun, Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific neutralizing antibodies for tracking immune escape variants, *Genome Medicine* 13 (2021), p. 164.
H. Yi, 2019 Novel Coronavirus Is Undergoing Active Recombination, *Clinical Infectious Diseases* 71 (2020), p. 884-887.

M. Yuan, D. Huang, C.-C.D. Lee, N.C. Wu, A.M. Jackson, X. Zhu, H. Liu, L. Peng, M.J. van Gils, R.W. Sanders, D.R. Burton, S.M. Reincke, H. Prüss, J. Kreye, D. Nemazee, A.B. Ward and I.A. Wilson, Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants, (2021), p. 2021.2002.2016.430500.

H. Zhou, B.M. Dcosta, N.R. Landau and T. Tada, Resistance of SARS-CoV-2 Omicron BA.1 and BA.2
Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies, *Viruses* 14 (2022).
T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D.R. Harris, A.S. Olia, C.A. Talana, E.S. Yang, M. Chen, M. Choe, W. Shi, I.-T. Teng, A. Creanga, C. Jenkins, K. Leung, T. Liu, E.-S.D. Stancofski, T. Stephens, B. Zhang, Y. Tsybovsky, B.S. Graham, J.R. Mascola, N.J. Sullivan and P.D. Kwong, Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529, (2021), p. 2021.2012.2027.474307.





Sequences over time in World



https://covspectrum.org/explore/World/AllSa mples/AllTimes/variants?variantQu ery=S%3A346&variantQuery1=S%3 A493&variantQuery2=S%3A444&an alysisMode=CompareEquals&